These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12429458)

  • 1. Deagglomeration of dry powder pharmaceutical aerosols.
    Voss A; Finlay WH
    Int J Pharm; 2002 Nov; 248(1-2):39-50. PubMed ID: 12429458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols.
    Longest PW; Son YJ; Holbrook L; Hindle M
    Pharm Res; 2013 Jun; 30(6):1608-27. PubMed ID: 23471640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of liposomes in dry powder form: aerodynamic dispersion properties.
    Desai TR; Hancock RE; Finlay WH
    Eur J Pharm Sci; 2003 Dec; 20(4-5):459-67. PubMed ID: 14659490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques.
    Louey MD; Van Oort M; Hickey AJ
    Pharm Res; 2004 Jul; 21(7):1200-6. PubMed ID: 15290860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring Bipolar Charge and Mass Distributions of Powder Aerosols by a Novel Tool (BOLAR).
    Wong J; Lin YW; Kwok PC; Niemelä V; Crapper J; Chan HK
    Mol Pharm; 2015 Sep; 12(9):3433-40. PubMed ID: 26222019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between inertial impaction and laser diffraction sizing data for aerosolized carrier-based dry powder formulations.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Pharm Res; 2006 Sep; 23(9):2200-9. PubMed ID: 16900411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.
    Martin GP; Marriott C; Zeng XM
    Pharm Res; 2007 Feb; 24(2):361-9. PubMed ID: 17177114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
    Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses.
    Coates MS; Fletcher DF; Chan HK; Raper JA
    Pharm Res; 2005 Jun; 22(6):923-32. PubMed ID: 15948036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Force control and powder dispersibility of spray dried particles for inhalation.
    Weiler C; Egen M; Trunk M; Langguth P
    J Pharm Sci; 2010 Jan; 99(1):303-16. PubMed ID: 19533606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of force control agents in high-dose dry powder inhaler formulations.
    Begat P; Morton DA; Shur J; Kippax P; Staniforth JN; Price R
    J Pharm Sci; 2009 Aug; 98(8):2770-83. PubMed ID: 19067395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
    Sethuraman VV; Hickey AJ
    AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Abbreviated Impactor Measurements (AIM) and Efficient Data Analysis (EDA) for Dry Powder Inhalers (DPIs) Against the Full-Resolution Next Generation Impactor (NGI).
    Mohan M; Lee S; Guo C; Peri SP; Doub WH
    AAPS PharmSciTech; 2017 Jul; 18(5):1585-1594. PubMed ID: 27624069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.
    Lucas P; Anderson K; Staniforth JN
    Pharm Res; 1998 Apr; 15(4):562-9. PubMed ID: 9587952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.